ARTICLE | Clinical News
Sotio's DCVAC/OvCa improves survival in Phase II for recurrent ovarian cancer
April 5, 2019 6:35 PM UTC
Sotio reported March 19 that DCVAC/OvCa as second-line treatment decreased the risk of death by 62% in the Phase II SOV02 trial to treat recurrent, platinum-sensitive epithelial ovarian cancer.
DCVAC/OvCa is an active cellular immunotherapy for ovarian cancer that uses a patient's dendritic cells to induce an immune reaction against presented tumor antigens...
BCIQ Company Profiles